Cell‐penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival
Tóm tắt
Most patients suffering from non–small cell lung cancer (NSCLC) have epidermal growth factor receptor (EGFR) overexpression. Currently, EGFR tyrosine kinase inhibitors (TKIs) that act as the ATP‐analogs and monoclonal antibodies (MAbs) to EGFR‐ectodomain that block intracellular signaling are used for the treatment of advanced NSCLC. Unfortunately, adverse effects due to the TKI off‐target and drug resistance occur in a significant number of the treated patients while some NSCLC genotypes do not respond to the therapeutic MAbs. Thus, a more effective remedy for the treatment of EGFR‐overexpressed cancers is deemed necessary. In this study, VH/VHH displayed‐phage clones that are bound to recombinant EGFR‐TK were fished‐out from a humanized‐camel VH/VHH phage display library. VH/VHH of three phage‐infected
Từ khóa
Tài liệu tham khảo
MosesE AllanE‐L2007. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX‐0081 (ANTI‐VWF)editor^editors Bio‐Medicine.org.
Ablynx. Comparative study of ALX‐0081 versus GPIIb/IIIa inhibitor in high risk percutaneous coronary intervention (PCI) patients. NIH; 2009.